Clinical Trials Directory

Trials / Terminated

TerminatedNCT02935101

Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
4 (actual)
Sponsor
Prof. Dominique de Quervain, MD · Academic / Other
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate whether prednisolone lowers intensity and frequency of craving in heroin-addicted subjects undertaking a detoxification of cocaine and/or heroin.

Detailed description

Participants of this study are 120 heroin-addicted patients who are inward for a detoxification program for either cocaine or cocaine and heroin. Depending on the detoxification substance(s) there will be two groups of participants: Detoxification of cocaine (A; 60 participants) and detoxification of heroin and cocaine (B; 60 participants). The detoxification starts mandatory with the admission to the ward and lasts about 1-2 weeks. The participation in the study lasts about 4-5 weeks (including follow-up visits). Intake of study medication starts two days after admission and one day after informed consent. Each participant will get either 30mg/d prednisolon or placebo during five days. Participants will be under normal medical supervision during the treatment phase until follow-up 2 (final examination) provided by ward staff. Treatment days and follow-up 1 and 2 consist of : (1) vital signs (BP, HR, temperature) as measured in the daily routine, (2) at midday: visual analogue scales asking about craving for heroin and cocaine at the moment, (3) afternoon: questionnaires to survey mainly the withdrawal symptoms and vegetative parameters.

Conditions

Interventions

TypeNameDescription
DRUGPrednisoloneformulated for oral administration. encapsulated.
DRUGPlacebo (for Prednisolone)Sugar pill manufactured to mimic Prednisolon 10mg capsules

Timeline

Start date
2016-10-01
Primary completion
2017-05-01
Completion
2017-05-01
First posted
2016-10-17
Last updated
2019-05-23

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT02935101. Inclusion in this directory is not an endorsement.